OBJECTIVES: Malignant pleural mesothelioma is an aggressive and rare malignancy that frequently recurs despite aggressive therapy. We evaluated the frequency of treatment with surgery, radiation or chemotherapy, changes in therapy and survival over time and factors associated with the receipt of trimodality therapy.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is an aggressive and rare malignancy that is usually fatal. MPM is challenging to treat due to significant heterogeneity in disease presentation and progression. Even after aggressive multimodality therapy, MPM will frequently recur. Unfortunately, the prognosis for mesothelioma within the USA has not changed significantly since the 1970s [1] . This is surprising, given the advancements in perioperative care and adjuvant radiation therapy and the introduction of platinum-folate-inhibitor doublet chemotherapy [2] [3] [4] . Nonetheless, several observational studies have reported survival benefit following trimodality therapy (surgery, chemotherapy and radiation), with a median survival ranging between 16 months and 29 months [5] [6] [7] [8] [9] [10] [11] . Although these results suggest that trimodality therapy is promising, its effectiveness has not been proved in large randomized trials.
There is a paucity of randomized data to guide treatment of mesothelioma. Conducting randomized trials for mesothelioma has been a formidable task due to the rarity of the disease as well as challenges with accrual and crossover. The only randomized trial for trimodality therapy for mesothelioma, the Mesothelioma and Radical Surgery (MARS) I trial, failed to show feasibility of randomizing patients between the trimodality arm (which included induction chemotherapy, extrapleural pneumonectomy †Presented at the 25th European Conference on General Thoracic Surgery, Innsbruck, Austria, 28-31 May 2017. ‡The second author and the last two authors contributed equally to this study. and adjuvant radiotherapy) and the chemotherapy-only arm. Although this small pilot study was not powered to demonstrate survival, patients in the trimodality arm fared worse than those in the chemotherapy-only arm. MARS II is currently studying the feasibility of conducting a randomized trial comparing pleurectomy and decortication with chemotherapy alone for the treatment of mesothelioma [12, 13] .
Our goal in this study was to use registry data to evaluate the evolution of treatment paradigms for mesothelioma in the USA and to identify factors that were associated with the receipt of trimodality therapy. Although the selection of treatment options is controversial, especially the inclusion of radiation therapy, we elected to focus on trimodality therapy because it is currently believed to be associated with longer survival than other regimens [14] .
MATERIALS AND METHODS
Patient data were identified using the National Cancer Database (NCDB), which is a joint programme sponsored by the Commission on Cancer (CoC) and the American Cancer Society. The NCDB is a hospital-based, nationwide registry that collects data from approximately 1500 CoC-accredited facilities and captures more than 70% of new cancer diagnoses [15] . The American College of Surgeons has executed a Business Associate Agreement that includes a data use agreement with each of its CoC-accredited hospitals. This study was approved by the MD Anderson Cancer Center Institutional Review Board with a waiver of individual informed consent.
Cohort identification
The NCDB participant user file was queried from 2004 to 2014 using the mesothelioma site code. Patients with pleural involvement, malignant histology or cytology were selected for further analysis.
Treatment definitions
Cancer-directed surgery was defined with the use of the following Surveillance, Epidemiology, and End Results (SEER) sitespecific codes: (30) simple/partial surgical removal of primary site; (40) total surgical removal of primary site; (50) surgery stated to be 'debulking' and (60) radical surgery. Specific surgical procedure could not be defined from the above surgical codes due to the lack of specialized SEER site-specific codes for the mesothelioma site. Furthermore, there is no centralized guidance for how a pleurectomy and decortication or extrapleural pneumonectomy should be coded within the FORDS manual, leaving each institution to interpret how a pleurectomy and decortication or extrapleural pneumonectomy should be coded [16] . However, a similar analytical approach has been previously utilized with other SEER and NCDB database studies of mesothelioma [1, 14] . Chemotherapy was defined as either single agent or multiagent. Radiation therapy was defined as the utilization of external beam radiation. Cases with codes indicating palliative therapy were considered to have undergone actual therapy, considering the controversial fact that all therapies for mesothelioma could be considered palliative.
Tumour characteristics and demographic definitions
Histology was defined according to the third edition of the International Classification of Diseases for Oncology (ICD-O-3) using codes 9050, 9051, 9052 or 9053. Patient income and education were estimated from the median household incomes within their zip code, and the proportion of regional non-high school graduates was obtained by the 2012 American Community Survey data. History of asbestos exposure was collected from 2010 onwards.
Statistical analysis
The Armitage test for trend was used for time-trend analysis. A logistic regression model was used to evaluate factors associated with the receipt of trimodality therapy. Variables studied in the model included age, gender, race, insurance status, median income, facility type, facility location, urban status, great circle distance, Charlson comorbidity score, histology and the American Joint Committee on Cancer (AJCC) clinical stage. Tumour size, grade and history of asbestos exposure were not included in the model due to >70% missing data. Missing data for clinical stage, urban status and insurance status were included as covariates in the model. Cases with missing facility type and location (n = 126) as well as missing income and distance to hospital (n = 522), were dropped from the model. Education level was not included in the model due to collinearity with income status.
Survival was evaluated with the Kaplan-Meier method using the log-rank test and stratified by the year of diagnosis. Median survival was calculated utilizing the Kaplan-Meier method. Survival time was defined according to the date of diagnosis, until the date of death or the last follow-up. The survival analysis was restricted to patients diagnosed in 2013 or earlier due to insufficient follow-up for patients diagnosed in 2014. P-values <0.05 were considered statistically significant, and all tests were 2 sided. All the statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS

Demographics
We initially identified 25 752 patients. After selecting for patients with pleural involvement, tissue or cytological confirmation and malignant histology according to ICD-O-3 codes, 20 561 patients were included in the final analysis. Median age at diagnosis was 74 (interquartile range 66-80, range 18-90+) years. There were 7210 (35%) cases that were diagnosed or treated at an academic or research centre, with 11 281 (57%) cases diagnosed or treated at either a Comprehensive Community Cancer Program or Community Cancer Program and 1944 (10%) at an Integrated Network Cancer Program (Table 1) . Overall, less patients presented with early-stage disease when compared with the more advanced disease, Stage I 3400 (17%), Stage II 2146 (10%), Stage III 3137 (15%), Stage IV 6834 (33%), and 5044 (25%) had documented an unspecified stage. A total of 14 173 (69%) patients presented with Charlson comorbidity score of 0, despite often advanced age. The most frequent histological subtype was epithelioid with 7727 (38%) cases, followed by sarcomatoid with 2581 (13%) cases and biphasic with 1546 (8%) cases; 8707 (42%) cases had unspecified histology. There were 7356 (36%) patients who were treated with chemotherapy alone and 4028 (20%) patients who were treated with cancer-directed surgery with or without adjunctive therapy (Table 2) . Additionally, 8616 (42%) patients underwent no mesothelioma-directed therapy of any kind and could be assumed to have received the best supportive care. Only 533 (2.6%) patients received trimodality therapy.
Trends in demographics and tumour characteristics
To assess for trends in demographics and tumour-related characteristics, as well as treatment, patients were evaluated for changes during the period of 2004-14 ( Fig. 1) . Although the number of cases has increased from 1752 to 1921 per year (P < 0.001), the proportion among patients less than 70 years has decreased from 42% to 36% (P < 0.001). More diagnoses have been observed in women, with an increase from 19.6% to 23.2% (P = 0.001). More patients have been presenting with clinical Stage I disease over time, from 12% to 19%, P < 0.001, possibly due to earlier detection from increased computed tomography scanning utilization or other factors. Cases with a documented history of asbestos exposure remained stable at 49% (P = 0.67).
Trends in treatment
Many patients did not receive any therapy directed for mesothelioma; however, the proportion of patients who received no therapy decreased from 45% to 36% (P < 0.001, Fig. 2 ). Overall, utilization of cancer-directed surgery increased slightly from 16% to 19% (P < 0.001). Appropriately, the proportion of patients who underwent cancer-directed surgery alone decreased from 6% to 4% (P = 0.006). There was a significant increase in the frequency of cancer-directed surgery combined with chemotherapy during the study period from 6% to 11% (P < 0.001). Overall utilization of chemotherapy increased from 41% to 53% (P < 0.001); however, trimodality therapy remained stable over time at 3% (P = 0.78). More patients were treated at academic centres in recent years, especially among those who received cancer-directed surgery, with an increase from 52% to 64% (P = 0.002). Multiagent chemotherapy use also increased from 80% to 94% among those who underwent cancer-directed surgery (P < 0.001). 
Trends in overall survival
Independent predictors for receipt of trimodality therapy
On multivariate analysis, patient-related factors such as older age and increasing comorbidities (reflected by a higher Charlson score) were associated with a lower likelihood of receiving trimodality therapy (Table 3) . Gender, race and residence in a zip code with higher median income were statistically significantly associated with the receipt of trimodality therapy on univariate analyses, although the associations were no longer present after adjustment for demographic and clinical variables. Sarcomatoid histology and clinical Stage IV disease were associated with decreased utilization of trimodality therapy. In addition, sociodemographic factors such as travel more than 26 miles and presence of private insurance were associated with increased receipt of trimodality therapy. We also explored a hypothesis whether the lower utilization of trimodality therapy could be explained by frequent ineligibility of patients for aggressive cytoreductive surgery. We defined an ideal surgical candidate as one who is less than 70 years, with a Charlson score of 0, clinical Stage I through III and with epithelioid histology (n = 3010). Even among this restricted subgroup, trimodality therapy continued to be infrequently given, with only 8% having received trimodality therapy. Similar results were observed for the combination of surgery with chemotherapy, where the rate was only 16%. The overwhelming majority of patients did not receive surgery-based multimodality therapy, even after selecting for hypothetical ideal surgical candidates.
DISCUSSION
Despite available treatment options, almost half of patients in the USA do not receive any cancer-directed therapy for MPM. The most common treatment is chemotherapy alone. Surgery-based multimodality therapy is uncommon and seemingly reserved only for select patients. However, the use of surgery with chemotherapy has been increasing, while the use of trimodality therapy remained stable over time. Treatment of mesothelioma with trimodality therapy remains highly specialized and is provided by only a limited number of centres. Access to care may be a possible limiting issue, as evidenced by the association between the use of trimodality therapy and socioeconomic factors.
Utilization of chemotherapy with or without cancer-directed surgery for MPM increased significantly over the study period from 2004 to 2014 and can be most likely attributed to the findings of 2 pivotal randomized Phase III trials published in 2003 and 2005. In these 2 trials, the chemotherapy doublet of platinum and pemetrexed or raltitrexed when compared with cisplatin alone was administered to 456 previously chemotherapy-naive patients who were not eligible for curative surgery [3, 4] . The chemotherapy doublets resulted in an increased median survival from 9 months to 12 months (hazard ratio 0.77). This relatively small, although statistically significant, clinical impact of the doublet chemotherapy suggests that robust welldesigned trials lead to incremental changes in the adoption of therapies for mesothelioma.
Previous studies using SEER population data have shown that the median survival for mesothelioma has not changed significantly in the last 4 decades [1] . Our study shows that median survival has increased from 8 months to 11 months during the period from 2004 to 2013 according to data within the NCDB. Furthermore, for patients who undergo cancer-directed surgery, median survival has increased from 12 months to 19 months. This encouraging trend parallels a concomitant increase in the utilization of chemotherapy as an adjunct to surgery. However, these results should be interpreted cautiously, as association does not imply causation. Other possibilities that may explain improved survival over time may be related to other less well-documented temporal changes or lead-time bias that occurs when survival appears to have increased because of earlier detection. Improved patient selection for surgical therapy is likely another factor influencing the results. An important point to also consider when relating NCDB data and SEER data is that the NCDB is a hospitalbased registry as opposed to a population-based registry. As a hospital-based registry, the data within the NCDB reflect patients who presented at CoC-accredited hospitals, which may reflect different treatment patterns and different referral patterns. The NCDB captures 70% of cancer patients in the USA, which is considered to be the strength of the database. Because the rate of cancer-directed surgery is remarkably similar to that published in the SEER database, at 20% vs 23%, suggesting that both databases capture similar patient populations [17] .
We also investigated factors associated with the receipt of trimodality therapy and found that sociodemographic factors including insurance status, median income and prolonged travel were associated with increased utilization of trimodality therapy, suggesting that access to care may be a significant factor limiting the receipt of trimodality therapy. Interestingly, even after restricting this analysis to patients who would be seemingly eligible for cytoreductive surgical therapy, many patients did not receive trimodality therapy or surgery with chemotherapy.
Limitations
There are several limitations to this study. First, as mentioned earlier, retrospective analyses can only demonstrate associations but cannot prove causation. Second, changes in several of the demographic-or tumour-related characteristics could also be influenced by variations in precision of reporting to the NCDB within the studied time period. For example, the finding that the proportion of clinical Stage I patients increased from 2004 to 2014 may have been related to a corresponding decrease in missing data for staging during this period, as well as to the evolution of radiographic imaging such as positron emission tomography, which became increasingly utilized during this time period.
CONCLUSION
In conclusion, the majority of patients with MPM are not treated with surgery-based multimodality therapy, although the use of chemotherapy and surgery with chemotherapy has increased over the last decade. There has been no change in the use of trimodality therapy over time, as this approach seems to be restricted only to the most specialized centres. The lack of Level I evidence of the benefit of trimodality therapy and the physiological challenge of tolerating all 3 treatment modalities are likely contributing to the underutilization of this aggressive treatment strategy. Even the use of therapies supported by the high level of evidence, such as chemotherapy, have only modestly increased over time. Given the rarity and the high lethality of disease, ideally all patients with MPM should be enrolled in clinical trials in the future to maximize the likelihood of identifying effective treatments. Additionally, diagnostic evaluation and treatment of rare diseases such as MPM should be centralized and provided at specialized centres. There are many exciting new therapies in the development for mesothelioma, including immunotherapy [18] , which hold the potential to transform the field and hopefully offer substantial improvements in survival.
